Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters

NCT01086501 is registered in ClinicalTrials.gov with Desitin Arzneimittel GmbH as lead sponsor.

NCT NCT01086501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01086501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of an ER-formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients Under Consideration of Quality of Life Parameters
Lead sponsor
Desitin Arzneimittel GmbH
Phase
Observational
Overall status
Completed
Start date
February 28, 2010
Completion date
October 31, 2012
Enrollment
225 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy